NIH is offering a grant for innovative research to explore the therapeutic potential of targeting Myeloid-Derived Suppressor Cells (MDSCs) in tuberculosis with HIV co-infection. The grant aims to investigate host-directed therapeutics and the impact of host-induced immunosuppression on Mycobacterium tuberculosis pathogenesis. Applications are welcome for both clinical and preclinical/non-clinical studies. Closing date for submissions is January 10, 2022.
Opportunity ID: 320196
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | PAR-19-364 |
Funding Opportunity Title: | Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.855 — Allergy and Infectious Diseases Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Sep 03, 2019 |
Last Updated Date: | Sep 03, 2019 |
Original Closing Date for Applications: | Jan 10, 2022 |
Current Closing Date for Applications: | Jan 10, 2022 |
Archive Date: | Feb 15, 2022 |
Estimated Total Program Funding: | – |
Award Ceiling: | $200,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Small businesses Independent school districts Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Native American tribal governments (Federally recognized) County governments Private institutions of higher education For profit organizations other than small businesses City or township governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) State governments |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical and preclinical/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-19-364.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
There are no related documents on this grant.
Packages
Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-F | Use for due dates on or before January 24, 2022 | PKG00259752 | Dec 06, 2019 | Jan 24, 2022 | View | |
FORMS-E | Use for due dates on or before May 24, 2020 | PKG00254503 | Dec 06, 2019 | May 24, 2020 | View | |
FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270247 | Nov 16, 2021 | Jan 10, 2022 | View |
Package 1
Mandatory forms
320196 RR_SF424_2_0-2.0.pdf
320196 PHS398_CoverPageSupplement_5_0-5.0.pdf
320196 RR_OtherProjectInfo_1_4-1.4.pdf
320196 PerformanceSite_2_0-2.0.pdf
320196 RR_KeyPersonExpanded_2_0-2.0.pdf
320196 PHS398_ResearchPlan_4_0-4.0.pdf
320196 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
320196 RR_Budget_1_4-1.4.pdf
320196 RR_SubawardBudget30_1_4-1.4.pdf
320196 PHS398_ModularBudget_1_2-1.2.pdf
320196 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
320196 RR_SF424_2_0-2.0.pdf
320196 PHS398_CoverPageSupplement_4_0-4.0.pdf
320196 RR_OtherProjectInfo_1_4-1.4.pdf
320196 PerformanceSite_2_0-2.0.pdf
320196 RR_KeyPersonExpanded_2_0-2.0.pdf
320196 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
320196 RR_Budget_1_4-1.4.pdf
320196 RR_SubawardBudget30_1_4-1.4.pdf
320196 PHS398_ModularBudget_1_2-1.2.pdf
320196 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 3
Mandatory forms
320196 RR_SF424_5_0-5.0.pdf
320196 PHS398_CoverPageSupplement_5_0-5.0.pdf
320196 RR_OtherProjectInfo_1_4-1.4.pdf
320196 PerformanceSite_4_0-4.0.pdf
320196 RR_KeyPersonExpanded_4_0-4.0.pdf
320196 PHS398_ResearchPlan_4_0-4.0.pdf
320196 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
320196 RR_Budget_3_0-3.0.pdf
320196 RR_SubawardBudget30_3_0-3.0.pdf
320196 PHS398_ModularBudget_1_2-1.2.pdf
320196 PHS_AssignmentRequestForm_3_0-3.0.pdf